NZ603345A - Stabilized ophthalmic galactomannan formulations - Google Patents

Stabilized ophthalmic galactomannan formulations

Info

Publication number
NZ603345A
NZ603345A NZ603345A NZ60334511A NZ603345A NZ 603345 A NZ603345 A NZ 603345A NZ 603345 A NZ603345 A NZ 603345A NZ 60334511 A NZ60334511 A NZ 60334511A NZ 603345 A NZ603345 A NZ 603345A
Authority
NZ
New Zealand
Prior art keywords
sorbitol
galactomannan
concentration
present
stabilized ophthalmic
Prior art date
Application number
NZ603345A
Other languages
English (en)
Inventor
David L Meadows
Howard Allen Ketelson
James W Davis
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of NZ603345A publication Critical patent/NZ603345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ603345A 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations NZ603345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33151110P 2010-05-05 2010-05-05
PCT/US2011/035165 WO2011140203A2 (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Publications (1)

Publication Number Publication Date
NZ603345A true NZ603345A (en) 2014-12-24

Family

ID=44626461

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603345A NZ603345A (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Country Status (16)

Country Link
US (2) US20110275593A1 (enExample)
EP (1) EP2566447B1 (enExample)
JP (1) JP5794744B2 (enExample)
KR (2) KR20180001587A (enExample)
CN (2) CN106389325A (enExample)
AR (1) AR081015A1 (enExample)
AU (1) AU2011248129B2 (enExample)
BR (1) BR112012028308B1 (enExample)
CA (1) CA2798069C (enExample)
ES (1) ES2809304T3 (enExample)
MX (1) MX2012012826A (enExample)
NZ (1) NZ603345A (enExample)
SG (2) SG10201804305SA (enExample)
TW (1) TWI606841B (enExample)
WO (1) WO2011140203A2 (enExample)
ZA (1) ZA201208199B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071834A1 (es) * 2008-04-26 2010-07-21 Alcon Res Ltd Sistema polimerico de lagrimas artificiales
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
UA113434C2 (uk) * 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
CA3285799A1 (en) * 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
TWI757773B (zh) 2019-06-28 2022-03-11 瑞士商愛爾康公司 眼用組成物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ, インコーポレーテッド 補体因子d媒介障害の処置用のヘテロアリール化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
AU2025233965A1 (en) 2024-03-04 2026-07-16 Alcon Inc. Carbamoylphenylboronic acid-containing acrylic monomers and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8028A (en) * 1851-04-08 Hokse-poweb
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
DE3827561C1 (enExample) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE69818675T2 (de) * 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
GB9808461D0 (en) * 1998-04-22 1998-06-17 Innovative Tech Ltd Solid borate-diol interaction products
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
WO2008036855A2 (en) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
TWI434926B (zh) 2006-12-11 2014-04-21 Alcon Res Ltd 眼用組成物中聚氧化乙烯-聚氧化丁烯(peo-pbo)嵌段共聚物之使用
AR066901A1 (es) * 2007-05-18 2009-09-23 Alcon Mfg Ltd Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas
AR071834A1 (es) * 2008-04-26 2010-07-21 Alcon Res Ltd Sistema polimerico de lagrimas artificiales
BRPI1008654A2 (pt) 2009-02-05 2016-03-08 Alcon Res Ltd processo para purificação de guar

Also Published As

Publication number Publication date
JP2013525493A (ja) 2013-06-20
ES2809304T3 (es) 2021-03-03
JP5794744B2 (ja) 2015-10-14
TWI606841B (zh) 2017-12-01
CA2798069C (en) 2016-07-05
WO2011140203A3 (en) 2012-04-19
US20130244971A1 (en) 2013-09-19
AU2011248129A1 (en) 2012-11-29
ZA201208199B (en) 2014-01-29
TW201141524A (en) 2011-12-01
SG185422A1 (en) 2012-12-28
US20110275593A1 (en) 2011-11-10
EP2566447B1 (en) 2020-07-15
EP2566447A2 (en) 2013-03-13
CN102939074A (zh) 2013-02-20
CN106389325A (zh) 2017-02-15
BR112012028308A2 (pt) 2016-11-01
MX2012012826A (es) 2013-01-28
WO2011140203A2 (en) 2011-11-10
KR20180001587A (ko) 2018-01-04
BR112012028308B1 (pt) 2021-09-28
US8846641B2 (en) 2014-09-30
KR20130060228A (ko) 2013-06-07
SG10201804305SA (en) 2018-06-28
AR081015A1 (es) 2012-05-30
CA2798069A1 (en) 2011-11-10
AU2011248129B2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
PH12015501421A1 (en) Long-acting formulations of insulin
MX2012006881A (es) Composiciones de povidona-yodo oftalmicas no irritantes.
PH12014502778A1 (en) Antibody formulation
AU2013334740A8 (en) Stable, low viscosity antibody formulation
BR112015000520A2 (pt) agente de espessamento estável com lipase
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
CO7151500A2 (es) Preparación inyectable
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
SG10201804305SA (en) Stabilized ophthalmic galactomannan formulations
IN2014MN01470A (enExample)
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX344795B (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a.
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
UA116886C2 (uk) Препаративна форма йодосульфурон-метилу натрієвої солі
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід
WO2014153009A3 (en) Thiosaccharide mucolytic agents
PH12014502571B1 (en) Ophthalmic compositions with improved dessication protection and retention
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CL2015002721A1 (es) Formulaciones oftálmicas
IN2014MN00929A (enExample)
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2016 BY FB RICE

Effective date: 20150325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2017 BY CPA GLOBAL

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2019 BY CPA GLOBAL

Effective date: 20180419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2020 BY CPA GLOBAL

Effective date: 20190418

ASS Change of ownership

Owner name: ALCON INC., CH

Effective date: 20191218

LAPS Patent lapsed